Last update 21 Nov 2024

Rogaratinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BAY 1163877盐酸盐
Target
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationSpecial Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC23H26N6O3S
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N
CAS Registry1443530-05-9

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Urothelial CarcinomaPhase 3
GB
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
TW
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
NL
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
SE
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
FI
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
FR
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
IL
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
HK
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
IE
31 May 2018
Locally Advanced Urothelial CarcinomaPhase 3
PT
31 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Metastatic urothelial carcinoma
First line
FGFR Positive
26
(jkubcvwypz) = The RP2D for R+A was 600 mg BID dcgsmctlet (hecahkodhp )
Positive
20 May 2021
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation)
Phase 1/2
27
(mibajytwno) = 63% zmpikscqku (feqbqiqegd )
Positive
25 May 2020
Phase 1
74
(frjolzdrgv) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. hvtyboixja (prrfihhpeb )
Positive
19 Feb 2020
Phase 1
866
(xumcngpnuk) = woquruiyob dfcxxrqpbl (mahppssdhl, 8·6 - 23·5)
-
01 Oct 2019
Phase 2
260
(yazolljzax) = 35% zppctkxcna (yvpjcimmzy )
Positive
26 May 2019
Phase 1
219
(tvqpzczjiz) = swogicndfx uafyqnnkfl (ovinythdub )
Positive
01 Jun 2018
Phase 1
219
(vlvqlbgxjm) = 49% tmqdsljfny (xhaeeqpkay )
-
26 Feb 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free